Skip to main content
Sarah Tasian, MD, Pediatric Hematology & Oncology, Philadelphia, PA, Children's Hospital of Philadelphia

SarahKathleenTasianMD

Pediatric Hematology & Oncology • Philadelphia, PA

Pediatric Hematologic Oncology

Associate Professor of Pediatrics; Children's Hospital of Philadelphia and University of Pennsylvania Perelman School of Medicine

Join to view full profile

Dr. Tasian is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Tasian's full profile

Already have an account?

Summary

  • Sarah K. Tasian, MD is a pediatric oncologist and physician-scientist at the Children’s Hospital of Philadelphia and University of Pennsylvania School of Medicine who is interested in development of molecularly-targeted therapeutics for children with high-risk leukemias. She is a graduate of the University of Notre Dame (BS, BA) and Baylor College of Medicine (MD), and she trained in Pediatrics at Seattle Children’s Hospital and in Pediatric Hematology-Oncology at University of California, San Francisco (UCSF). She specialises in the clinical care of children with hematologic malignancies and is an internationally-recognized expert in pediatric ALL and AML. Her bench-to-bedside and bedside-back-to-bench translational laboratory research program focuses upon testing of kinase inhibitors and chimeric antigen receptor (CAR) T cell immunotherapies in genetic subsets of childhood ALL and AML. Dr Tasian has leadership roles in the Children’s Oncology Group (COG) ALL and Myeloid Diseases committees and Leukemia Lymphoma Society PedAL/EuPAL consortium, is the COG Developmental Therapeutics committee Vice-Chair of Biology for Hematologic Malignancies, and leads or co-leads several national or international early phase clinical trials testing precision medicine therapies in children with high-risk leukemias.

Education & Training

  • University of California (San Francisco)
    University of California (San Francisco)Fellowship, Pediatric Hematology/Oncology, 2007 - 2011
  • University of Washington
    University of WashingtonResidency, Pediatrics, 2004 - 2007
  • Baylor College of Medicine
    Baylor College of MedicineClass of 2004
  • Howard Hughes Medical Institute-National Institutes of Health Research Scholars Program
    Howard Hughes Medical Institute-National Institutes of Health Research Scholars ProgramResearch fellowship, Tumor immunology, 2001 - 2002

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 2011 - 2024
  • CA State Medical License
    CA State Medical License 2007 - 2011
  • WA State Medical License
    WA State Medical License 2004 - 2007
  • American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

  • Alpha Omega Alpha Baylor College of Medicine, 2004
  • Phi Beta Kappa University of Notre Dame, 1998

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Targeting EIF4E Signaling with Ribavirin in Infant Acute Lymphoblastic Leukemia  
    Nyla A Heerema, James W Davenport, Carolyn A Felix, Andrew J Carroll, ZoAnn E Dreyer, Alix E Seif, David T Teachey, Joanne M Hilden, Sarah K Tasian, Cheryl L Willman, ..., Nature
  • Mutation-Specific Signaling Profiles and Kinase Inhibitor Sensitivities of Juvenile Myelomonocytic Leukemia Revealed by Induced Pluripotent Stem Cells  
    Stella T Chou, Jessica A Casas, Mignon L Loh, Sarah K Tasian, Nature

Abstracts/Posters

  • Correlation of CD123 Expression Level with Disease Characteristics and Outcomes in Pediatric Acute Myeloid Leukemia: A Report from the ChildrenÍs Oncology Group
    Sarah K. Tasian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Oncogene-Independent Adaptation of Pre-B Cell Receptor Signaling Confers Drug Resistance and Signaling Plasticity in Ph-like ALL
    Sarah K. Tasian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • DYRK1A Is Regulated By Oncogenic KMT2A and Required for Survival of KMT2A-Rearranged Acute Lymphoblastic Leukemia
    Sarah K. Tasian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Lectures

  • Expanding Horizons for Immunotherapy in Pediatric Leukemia 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-Risk Leukemias: A Report from the LEAP ConsortiumClinically Relevant Abstract 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Immunophenotypic and Genetic Overlap between JMML and CMML 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Press Mentions

  • Exploring JAK/STAT Inhibition in the Prevention and Treatment of B-ALL
    Exploring JAK/STAT Inhibition in the Prevention and Treatment of B-ALLOctober 7th, 2022
  • Emily Whitehead, First Pediatric Patient to Receive CAR T-cell Therapy, Celebrates Cure 10 Years Later
    Emily Whitehead, First Pediatric Patient to Receive CAR T-cell Therapy, Celebrates Cure 10 Years LaterMay 11th, 2022
  • Aberrant Splicing of CD22 in Acute Lymphoblastic Leukemia Underlies Resistance to Immunotherapy
    Aberrant Splicing of CD22 in Acute Lymphoblastic Leukemia Underlies Resistance to ImmunotherapyJanuary 4th, 2022
  • Join now to see all

Grant Support

  • Towards Rational Design of Combination Therapeutic TargetsNational Cancer Institute2020–2025
  • Combinatorial Precision Medicine Approaches to Overcome Immunotherapeutic Resistance in High-Risk Childhood LeukemiasLisa Dean Moseley Foundation2021–2024
  • Children’s Oncology Group Pediatric Early Phase Clinical Trial NetworkNational Cancer Institute2018–2023
  • Combinatorial Immunotherapeutic Targeting of Cytokine Receptor Kinase Signaling in CRLF2-R ALLDepartment of Defense2018–2023
  • Multispecific Targeting Incorporating Cytokine Receptor Pathways in High Risk Pediatric Acute Leukemias to Improve Durability of Adoptive Cell Therapy-Induced RemissionsNational Cancer Institute2018–2023
  • Precision Targeting of CRLF2-Driven Signaling in Childhood Ph-like ALLV Foundation Translational Research Grant Program2019–2022
  • K08 Mentored Career Development AwardNational Cancer Institute2014–2019

Professional Memberships

Hospital Affiliations

External Links

Dr. Sarah Tasian, Dr. Sarah Tasian, MD, Dr. S Tasian, Dr. Sarah Kathleen Tasian